Arena Pharmaceuticals (ARNA) Stock Price Up 10.9%

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s share price rose 10.9% during trading on Wednesday . The stock traded as high as $36.40 and last traded at $40.17. Approximately 1,234,737 shares traded hands during mid-day trading, an increase of 94% from the average daily volume of 636,050 shares. The stock had previously closed at $36.21.

ARNA has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Arena Pharmaceuticals in a research report on Monday, September 25th. BidaskClub raised Arena Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 2nd. Finally, Wells Fargo & Co raised Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Arena Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $36.00.

The company has a quick ratio of 4.32, a current ratio of 4.42 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1,577.21, a PE ratio of -44.19 and a beta of 1.50.

Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.01. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The business had revenue of $7.95 million for the quarter, compared to the consensus estimate of $5.48 million. During the same quarter in the prior year, the company earned ($0.05) EPS. The business’s revenue was down 58.6% compared to the same quarter last year. equities analysts forecast that Arena Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Balyasny Asset Management LLC bought a new position in shares of Arena Pharmaceuticals during the 2nd quarter worth $12,183,000. Pictet Asset Management Ltd. purchased a new stake in shares of Arena Pharmaceuticals during the 3rd quarter worth $13,656,000. Point72 Asset Management L.P. purchased a new stake in shares of Arena Pharmaceuticals during the 3rd quarter worth $9,973,000. JPMorgan Chase & Co. lifted its stake in shares of Arena Pharmaceuticals by 16,992.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 317,754 shares of the biopharmaceutical company’s stock worth $5,361,000 after purchasing an additional 315,895 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Arena Pharmaceuticals during the 3rd quarter worth $5,100,000. 72.82% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Arena Pharmaceuticals (ARNA) Stock Price Up 10.9%” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

About Arena Pharmaceuticals

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit